## SCHUCHERT JOSEPH S

Form 4
November 22, 2005

| RM 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION <br> Washington, D.C. 20549 | OMB APPROVAL |  |  |
| :---: | :---: | :---: | :---: | :---: |
|  |  | OMB <br> Number: | 3235 |  |
| Check this box if no longer | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | Expires: |  |  |
| subject to Section 16 |  | Estimated average burden hours per response... |  |  |
| Form 4 or |  |  |  |  |
| Form 5 <br> obligations may continue | Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section |  |  |  |
| See Instruction | 30(h) of the Investment Company Act of 1940 |  |  |  |
| 1(b). |  |  |  |  |

(Print or Type Responses)

| 1. Name and Address of Reporting Person **KELSO INVESTMENT ASSOC V |  |  | 2. Issuer Name and Ticker or Trading |
| :---: | :---: | :---: | :---: |
|  |  |  | Symbol |
| L P |  |  | ENDO PHARMACEUTICALS |
|  |  |  | HOLDINGS INC [ENDP] |
| (Last) | (First) | (Middle) | 3. Date of Earliest Transaction |
|  |  |  | (Month/Day/Year) |
| 320 PARK AVENUE, |  |  | 11/16/2005 |
| (Street) |  |  | 4. If Amendment, Date Original |
|  |  |  | Filed(Month/Day/Year) |

NEW YORK, NY 10022
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director
below)
Officer (give title
$\frac{\text { below) }}{\text { O }}$ Other (specify
6. Individual or Joint/Group Filing(Check

Applicable Line)
Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of

Security
(Instr. 3)
2. Transaction Date (Month/Day/Year)

2A. Deemed
Execution Date, if any (Month/Day/Year) (Instr. 8) $\quad$ (Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
6. Ownership 7. Nature of Form: Direct Indirect (D) or Beneficial Indirect (I) Ownership (Instr. 4) (Instr. 4)

|  |  | (A) | Reported <br> Transaction(s) |
| :---: | :---: | :---: | :--- |
| Code V Amount | or | (D) | Price |
| (Instr. 3 and 4) |  |  |  |

By Endo Pharma LLC ${ }^{(2)}$ (3)
Common
Stock, par
value $\$ .01$
per share ${ }^{(1)}$
Common
Stock, par
value $\$ .01$
per share ${ }_{-1}{ }^{(1)}$
Common

| Stock, par <br> value $\$ .01$ | $11 / 16 / 2005$ | X | 8,361 | D | $\$ .42$ | $17,586,178$ | I | By Endo <br> Pharma |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| per ${ }^{(2)}$ (3) |  |  |  |  |  |  |  |  |


| Common |  |  |  |  |  |  |  |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| Stock, par <br> value $\$ .01$ <br> per share $\underline{(1)}$ | $11 / 16 / 2005$ | X | 816 | D | $\$ 3$ | $17,585,362$ | I |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02) required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative | 2. Conversion | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if | 4. <br> Transactio | 5. Number of Derivative | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Security | or Exercise |  |  | Code | Securities | (Month/Day/Year) | (Instr. 3 and 4) |
| (Instr. 3) | Price of |  | (Month/Day/Year) | (Instr. 8) | Acquired |  |  |
|  | Derivative |  |  |  | (A) or |  |  |
|  | Security |  |  |  | Disposed of (D) |  |  |
|  |  |  |  |  | (Instr. 3, 4, |  |  |

Amount

| Date | Expiration | Title | or <br> Exercisable |
| :--- | :--- | :--- | :--- |
| Number <br> of |  |  |  |
|  |  |  | Shares |


| Call Option <br> (obligation <br> to sell) | $\$ 2.42$ | $11 / 16 / 2005$ | X | 2,676 | $10 / 13 / 2005$ | $08 / 26 / 2007$ | Common |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| 2,676 |  |  |  |  |  |  |  |


| Call Option <br> (obligation <br> to sell) | $\$ 2.42$ | $11 / 16 / 2005$ | X | 122 | $10 / 13 / 2005$ | $08 / 26 / 2007$ | Common | 122 |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| Stock |  |  |  |  |  |  |  |  |


| Call Option <br> (obligation <br> to sell) | $\$ 2.42$ | $11 / 16 / 2005$ | X | 8,361 | $10 / 13 / 2005$ | $08 / 26 / 2007$ | Common <br> Stock |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| Call Option | $\$ 3,361$ |  |  |  |  |  |  |
| (obligation <br> to sell) | $\$ 3$ | $11 / 16 / 2005$ | $X$ | 816 | $10 / 13 / 2005$ | $08 / 26 / 2007$ | Common <br> Stock |

## Reporting Owners

Reporting Owner Name / Address

## Relationships

Director 10\% Owner Officer Other

X
KELSO INVESTMENT ASSOC V L P
320 PARK AVENUE
NEW YORK, NY 10022
NICKELL FRANK T
C/O KELSO \& COMPANY
320 PARK AVENUE
NEW YORK, NY 10022
BERNEY PHILIP E
C/O KELSO \& COMPANY
320 PARK AVENUE
NEW YORK, NY 10022
BYNUM FRANK K
C/O KELSO \& COMPANY
320 PARK AVENUE
NEW YORK, NY 10022
WALL THOMAS R IV
C/O KELSO \& COMPANY
320 PARK AVENUE
NEW YORK, NY 10022
GOLDBERG MICHAEL B
C/O KELSO \& COMPANY 320 PARK AVENUE X ..... X
NEW YORK, NY 10022
MATELICH GEORGE E
C/O KELSO \& COMPANY
320 PARK AVENUE
NEW YORK, NY 10022
SCHUCHERT JOSEPH S
C/O KELSO \& COMPANY
320 PARK AVENUEX
NEW YORK, NY 10022
WAHRHAFTIG DAVID I
C/O KELSO \& COMPANY
320 PARK AVENUE
NEW YORK, NY 10022
Loverro Frank J
320 PARK AVENUE ..... X
NEW YORK, NY 10022
Signatures
/s/James J.Connors, II

## Edgar Filing: SCHUCHERT JOSEPH S - Form 4

## Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. $78 \mathrm{ff}(\mathrm{a})$.
(1) Kelso Investment Associates V, L.P. ("KIA V") is the designated filer.

KIA V may be deemed to share beneficial ownership of shares of Common Stock owned of record by Endo Pharma LLC by virtue of its
(2) status as a member of Endo Pharma LLC. KIA V shares investment and voting power along with the other members of Endo Pharma LLC with respect to securities owned by Endo Pharma LLC, but disclaims beneficial ownership of such securities except to the extent of its pecuniary interest.

Each individual reporting person may be deemed to share beneficial ownership of shares of Common Stock owned of record by KIA V,
(3) by virtue of his status as a general partner of the general partner of KIA V, and each individual shares investment and voting power along with the other general partners of KIA V, but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

